Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948553 · ClinicalTrials.gov registry record · Phase 2
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
A Phase 2 study of Post Traumatic Stress Disorder, sponsored by Global Coalition for Adaptive Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 10
- Study locations
NCT05948553: Recruiting Phase 2 study of Post Traumatic Stress Disorder, sponsored by Global Coalition for Adaptive Research.
NCT05948553 is a Phase 2 study of Post Traumatic Stress Disorder that is actively recruiting participants, run by Global Coalition for Adaptive Research. The registered enrollment target is 200 participants, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (70% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948553, a Phase 2 study of Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Global Coalition for Adaptive Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention A - Fluoxetine will assess the safety and efficacy of fluoxetine in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
Conditions Studied
Interventions
- DRUG Intervention A Fluoxetine Hydrochloride (HCl)
- DRUG Intervention A Placebo
Study Locations (10)
Arizona
- Phoenix VA Healthcare System - Phoenix
Florida
- Homestead Associates in Research, Inc. - Miami
Georgia
- Advanced Discovery Research - Atlanta
Hawaii
- Tripler Army Medical Center (TAMC) - Tripler AMC
Kentucky
- Cincinnati Veteran's Affairs Medical Center - Fort Thomas
Maryland
- Walter Reed National Military Medical Center (WRNMC) - Bethesda
New York
- Upstate Clinical Research Associates, LLC - Williamsville
Texas
- Wilford Hall Ambulatory Surgical Center (WHASC) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT05948553 shows while recruiting
NCT05948553 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Intervention A Fluoxetine Hydrochloride (HCl) is the first listed.
NCT05948553 lists 10 locations in 10 states (Arizona, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT05948553 about?
NCT05948553 is a clinical study titled "Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine". This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention A - Fluoxetine will assess the safety and efficacy of fluoxetine in participants with PTS...
What is the current status of trial NCT05948553?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2023-11-02. Estimated completion is 2026-09.
What conditions does trial NCT05948553 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT05948553?
The interventions under investigation include: Intervention A Fluoxetine Hydrochloride (HCl) (DRUG), Intervention A Placebo (DRUG).
Who is sponsoring clinical trial NCT05948553?
This trial is sponsored by Global Coalition for Adaptive Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948553 being conducted?
This trial has 10 study locations across Arizona, Florida, Georgia, Hawaii, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05948553's enrollment target sits among peer trials
200 47th of 262 higher than 207 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
RECRUITING · Phase 2
-
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
RECRUITING · Phase 2
-
MDMA for AUD/PTSD Comorbidity
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
-
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI